Related Experiment Video
Updated: Apr 26, 2026
26:48
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
17.7K
Subacute delayed ascending myelopathy: not just a post-traumatic disorder
1Spinal Cord Injuries Unit, Royal North Shore Hospital, Sydney, NSW, Australia.
Spinal Cord
|August 2, 2014
Summary
Subacute delayed ascending myelopathy (SDAM) is a rare spinal cord complication. This case report highlights its occurrence in non-traumatic injuries, suggesting a vascular mechanism and advocating for SDAM as the standard term.
Area of Science:
- Neurology
- Spinal Cord Injury Research
Background:
- Subacute delayed ascending myelopathy (SDAM) is a rare neurological complication following spinal cord injury (SCI).
- The etiology, pathogenesis, and optimal management of SDAM remain poorly understood.
- Radiological and clinical features are crucial for diagnosis.
Observation:
- This report details two cases with radiological findings consistent with SDAM.
- It includes the first reported case of SDAM following a non-traumatic SCI.
- The cases suggest a potential vascular mechanism contributing to the pathogenesis.
Findings:
- SDAM is an early neurological complication of SCI.
- A vascular mechanism is implicated in the pathogenesis of SDAM.
- Ascending myelopathy in stable SCI warrants clinical attention.
Implications:
- Increased awareness and further characterization of SDAM are needed.
- The proposed terminology 'SDAM' should be adopted for consistency.
- Understanding the pathogenesis may lead to improved management strategies for SCI complications.
More Related Videos
06:35In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
Published on: June 15, 2018
22.7K
08:16Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
33.3K
Related Concept Videos
01:25Secondary Spinal Cord Injury llI: Pathophysiology
40
Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
40
01:27Esophageal Achalasia
37
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide...
37
01:19Multiple Sclerosis l: Introduction
16
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
16
01:22Myasthenia Gravis ll: Pathophysiology
44
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
44
01:20Myasthenia Gravis: Overview and Treatment
3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
01:15Myasthenia Gravis: Diagnostic Tests
3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K